Troponin-T monitoring in outpatients with nonischemic heart failure;Valor de la determinación seriada de troponina T en pacientes ambulatorios con insuficiencia cardiaca no isquémica

Revista Espanola de Cardiologia

Volumn 61, Issue 7, 2008, Pages 678-686

  Pascual Figal, Domingo A ^a   Manzano Fernández, Sergio ^a   Pastor, Francisco ^a   Garrido, Iris P ^a   Casas, Teresa ^a   Mas, Jesús Sánchez ^a   Ansaldo, Pilar ^a   Martínez, Pedro ^a   Valdés, Mariano ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Heart failure; NT proBNP; Prognosis; Troponin T

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; TROPONIN T;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART FAILURE; HEART GRAFT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC HEART FAILURE; OUTPATIENT CARE; PATIENT MONITORING; PREDICTIVE VALIDITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL;

EID: 47749119946     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13123988     Document Type: Article

References (30)

1. Rodríguez-Artalejo F, Banegas JR, Guallar-Castillón P. Epidemiología de la insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:163-70.
2. Santaló Bel M, Guindo Soldevila J, Ordóñez Llanos J. Marcadores biológicos de necrosis miocárdica. Rev Esp Cardiol. 2003;56:703-20.
3. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al; on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-38.
4. La VL, Mezzena G, Zanolla L, Paccanaro M, Varotto L, Bonanno C, et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant. 2000;19:644-52.
5. Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol. 1999;84:608-11.
6. Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 2002;89:691-5.
7. Taniguchi R, Sato Y, Nishio Y, Kimura T, Kita T. Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels. 2006;21:344-9.
8. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001;103:369-74.
9. Logeart D, Beyne P, Cusson C, Tokmakova M, Leban M, Guiti C, et al. Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. Am Heart J. 2001;141:247-53.
10. Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation. 2004;110:2376-82.
11. Hudson MP, O'Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J. 2004;147:546-52.
12. Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116:249-57.
13. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guías de práctica clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Rev Esp Cardiol. 2005;58:1062-92.
14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-63.
15. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113:1958-65.
16. La VL, Mezzena G, Ometto R, Finocchi G, Bedogni F, Soffiati G, et al. Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am J Cardiol. 1997;80:88-90.
17. Sato Y, Taniguchi R, Makiyama T, Nagai K, Okada H, Yamada T, et al. Serum cardiac troponin T and plasma brain natriuretic peptide in patients with cardiac decompensation. Heart. 2002;88:647-8.
18. Perna ER, Macin SM, Cimbaro Canella JP, Szyszko A, Franciosi V, Vargas MW, et al. Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure. J Heart Lung Transplant. 2006;25:1230-40.
19. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833-8.
20. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J. 1999;138:95-9.
21. Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS. Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clin Cardiol. 2007;30:245-50.
22. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 1995;91:2504-7.
23. Beranek JT. Cardiomyocyte apoptosis contributes to the development of catacholamine cardiomyopathy. Clin Chim Acta. 2001;308:183-6.
24. Banki NM, Kopelnik A, Dae MW, Miss J, Tung P, Lawton MT, et al. Acute neurocardiogenic injury after subarachnoid hemorrhage. Circulation. 2005;112:3314-9.
25. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998;98:1329-34.
26. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
27. Jane-Wit D, Altuntas CZ, Johnson JM, Yong S, Wickley PJ, Clark P, et al. Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation. 2007;116:399-410.
28. Prabhu SD, Wang G, Luo J, Gu Y, Ping P, Chandrasekar B. Beta-adrenergic receptor blockade modulates Bcl-X(S) expression and reduces apoptosis in failing myocardium. J Mol Cell Cardiol. 2003;35:483-93.
29. Sabbah HN, Sharov VG, Gupta RC, Todor A, Singh V, Goldstein S. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol. 2000;36:1698-705.
30. Bayés-Genís A. NT-proBNP circulante, un nuevo biomarcador para el diagnóstico del paciente con disnea aguda. Rev Esp Cardiol. 2005;58:1142-4.